Acticor Biotech SAS

ALACT

FR0014005OJ5

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
4.05 ^EUR	+1.50%		+14.08%	+39.66%

Apr. 16	Acticor Biotech: phase 2/3 results expected in May	CF
Apr. 15	Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024	CI

Acticor Biotech SAS has filed an IPO.

September 28, 2021 at 12:00 am EDT

Acticor Biotech SAS has filed an IPO. Security Name: Shares Security Type: Common Stock

Latest news about Acticor Biotech SAS

Acticor Biotech: phase 2/3 results expected in May	Apr. 16	CF
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024	Apr. 15	CI
Acticor Biotech: falls after capital increase	Mar. 15	CF
Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	Mar. 15	MT
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack	Feb. 07	CI
Acticor: 'we are delighted to observe the market's reaction'.	Jan. 29	CF
Acticor Biotech continues to soar, hopes for stroke treatment	Jan. 24	CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal	Jan. 23	CI
Acticor: capital increase at a significant discount	Nov. 28	CF
Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	Nov. 07	MT
ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke	Nov. 07	CI
Acticor Biotech SAS Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-26	CI
Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks	23-09-07	CI
Acticor Biotech Announces Results of Its Collaboration with Brainomix Limited	23-08-31	CI
Acticor Biotech Announces Progress in Discussions with EU and US Regulatory Agencies	23-05-30	CI
Acticor Biotech SAS Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Acticor Biotech Announces Enrollment of More Than 240 Patients in the ACTISAVE Phase 2/3 Study in Stroke and Regulatory Progress with the EMA and FDA	23-03-23	CI
Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	23-03-09	MT
Acticor Biotech SAS announced that it has received €10 million in funding	23-03-07	CI
Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director	23-02-06	CI
Acticor Biotech SAS Provides an Update on the Progress of Its Clinical Programs with Glenzocimab	23-01-09	CI
Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	22-12-23	MT
Acticor Biotech SAS Provides an Update on the US Regulatory Discussion with the FDA	22-12-23	CI
Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	22-12-05	MT
Acticor Biotech Receives European Medicines Agency Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke	22-12-05	CI

Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II/III clinical development (Glenzocimab).

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.05 EUR

Average target price

10 EUR

Spread / Average Target

+146.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTICOR BIOTECH SAS	+39.66%	56.72M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.37%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.40%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs